Ariad Pharmaceuticals, Inc. (ARIA) Announces Ponatinib Presentations at Annual American Society of Hematology Meeting
12/3/2012 10:48:40 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, December 8 to 11, 2012. Updated and new results on the PACE trial will be featured in five presentations – two oral and three posters. PACE Trial: 12-Month Follow Up in Chronic Phase Patients. Title: A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial.